Company intelligence / Profile preview

SNJ Medical

Los Angeles, California, United Statessnjpharma.com ↗
Ownership
Private
Development stage
Other
01

Overview

SNJ Pharma is developing SNJ101, the first plasmin-independent thrombolytic agent, designed to avoid the bleeding complications of tPA/TNK; clinical results are not yet available.

Therapeutic areas
HematologyCardiovascular
Modalities
Small molecule
Industry
Biotech
02

Partnerships

BioLabs-LA at Lundquist Institute for Biomedical Innovation

Beyond the preview

Go deeper on SNJ Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNJ Medical.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call